

Supplementary Material

Title: The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: A comprehensive meta-analysis


Constantinos Roufas ^{1,2}, Dimitrios Chasiotis ¹, Anestis Makris ¹, Christodoulos Efstathiades ², Christos Dimopoulos ², Apostolos Zaravinos ^{1,*}

¹ Department of Life Sciences, Biomedical Sciences Program, School of Sciences, European University Cyprus, Nicosia, Cyprus.


² The Center for Risk and Decision Sciences (CERIDES), Department of Computer Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus.

*** Correspondence: Apostolos Zaravinos, PhD. Biomedical Sciences Program, Department of Life Sciences, School of Sciences, European University Cyprus. 6, Diogenes Str. Engomi, P.O. Box 22006, 1516, Nicosia, Cyprus. Tel: +357-22559577. Email: a.zaravinos@euc.ac.cy**


Supplementary Figures



Ovarian Cancer



Stomach Adenocarcinoma






Figure S1. In liver hepatocellular carcinoma (TCGA-LIHC) only the individual high levels of PRF1 and GZMA were significantly associated with a positive effect on patient survival. A similar non-significant association of (individual or simultaneous) high GZMA and PRF1 expression with better effect on patient survival could also be observed in mesothelioma (TCGA-MESO), ovarian cancer (GSE13876 and GSE49997), stomach adenocarcinoma (TCGA-STAD), thyroid carcinoma (TCGA-THCA) and uterine corpus endometrial carcinoma (TCGA-UCEC).